Vir Biotechnology, Inc. Increase (Decrease) in Accounts Receivable
Vir Biotechnology, Inc. (VIR) reported Increase (Decrease) in Accounts Receivable of $6.51 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2025-02-27
- Vir Biotechnology, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-12-31 was $8.75M, a 142.57% increase year-over-year.
- Vir Biotechnology, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-09-30 was $54.00K.
- Vir Biotechnology, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-06-30 was -$2.69M.
- Vir Biotechnology, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-03-31 was $401.00K.
- Vir Biotechnology, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $6.51M, a 1052.74% increase from fiscal 2023.
- Vir Biotechnology, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $565.00K.
- Vir Biotechnology, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$770.04M, a 199.61% decline from fiscal 2021.
- Vir Biotechnology, Inc. increase (decrease) in accounts receivable for fiscal 2021 was $773.08M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2024-12-31 | $8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $8.80M derived: sum of 2 quarters · filed 2025-02-27 | $6.11M derived: sum of 3 quarters · filed 2025-02-27 | $6.51M 10-K · filed 2025-02-27 |
| 2024-09-30 | $54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$2.63M derived: sum of 2 quarters · filed 2024-11-04 | -$2.23M 10-Q · filed 2024-11-04 | $1.37M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | -$2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$2.29M 10-Q · filed 2024-08-01 | $1.32M derived: sum of 3 quarters · filed 2025-02-27 | $1.32M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | $401.00K 10-Q · filed 2024-05-03 | $4.01M derived: sum of 2 quarters · filed 2025-02-27 | $4.01M derived: sum of 3 quarters · filed 2025-02-27 | $3.06M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.61M derived: sum of 2 quarters · filed 2025-02-27 | $2.66M derived: sum of 3 quarters · filed 2025-02-27 | $565.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$948.00K derived: sum of 2 quarters · filed 2024-11-04 | -$3.04M 10-Q · filed 2024-11-04 | -$281.21M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$948.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$3.04M 10-Q · filed 2024-08-01 | -$281.21M derived: sum of 3 quarters · filed 2025-02-27 | -$339.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$2.09M 10-Q · filed 2024-05-03 | -$280.26M derived: sum of 2 quarters · filed 2025-02-27 | -$338.44M derived: sum of 3 quarters · filed 2025-02-27 | -$1.22B derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$278.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$336.35M derived: sum of 2 quarters · filed 2025-02-27 | -$1.22B derived: sum of 3 quarters · filed 2025-02-27 | -$770.04M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$58.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$941.95M derived: sum of 2 quarters · filed 2023-11-03 | -$491.87M 10-Q · filed 2023-11-03 | $188.20M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$883.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$433.69M 10-Q · filed 2023-08-04 | $246.39M derived: sum of 3 quarters · filed 2024-02-26 | $339.39M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $450.08M 10-Q · filed 2023-05-08 | $1.13B derived: sum of 2 quarters · filed 2024-02-26 | $1.22B derived: sum of 3 quarters · filed 2024-02-26 | $1.22B derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $680.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $773.08M derived: sum of 2 quarters · filed 2024-02-26 | $773.08M derived: sum of 3 quarters · filed 2024-02-26 | $773.08M 10-K · filed 2024-02-26 |
| 2021-09-30 | $93.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $93.00M derived: sum of 2 quarters · filed 2022-11-03 | $93.00M 10-Q · filed 2022-11-03 | $93.00M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |